Replimune JP Morgan Healthcare Conference 2025 Presentation.pdf

1、Igniting a systemic immune response to cancer with oncolytic immunotherapyJP Morgan Healthcare ConferenceJanuary 13,20252JP Morgan Healthcare Conference 2025 Replimune Group Inc.Safe HarborAny statements contained herein that are not statements of historical facts may be deemed to be forward-looking

2、 statements withinthe meaning of Section 27A of the Securities Act of 1933,as amended,and Section 21E of the Securities Exchange Act of 1934,asamended,including statements regarding the advancement,timing and sufficiency of our clinical trials or financial status,patientenrollments in our existing a

3、nd planned clinical trials and the timing thereof,the results of our clinical trials,the timing and release of ourclinical data,statements regarding our expectations about our cash runway,our goals to develop and commercialize our productcandidates,our expectations regarding the size of the patient

4、populations for our product candidates if approved for commercial useand other statements identified by words such as“could,”“expects,”“intends,”“may,”“plans,”“potential,”“should,”“will,”“would,”orsimilar expressions and the negatives of those terms.Forward-looking statements are not promises or gua

5、rantees of futureperformance,and are subject to a variety of risks and uncertainties,many of which are beyond our control,and which could causeactual results to differ materially from those contemplated in such forward-looking statements.These factors include risks related to ourlimited operating hi

6、story,our ability to generate positive clinical trial results for our product candidates,the costs and timing ofoperating our in-house manufacturing facility,the timing and scope of regulatory approvals,changes in laws and regulations to whichwe are subject,competitive pressures,our ability to ident